ArticleJournal of hepatocellular carcinoma2026
HCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Changing epidemiology and etiology of hepatocellular carcinoma in Europe: implications for clinical practice and health policy.The Lancet regional health. Europe · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Hepatocellular carcinoma (HCC) may develop in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) even in the absence of cirrhosis. Whether the risk of HCC in non-cirrhotic MASLD is substantial to justify surveillance, and which patients may benefit, remains unclear. Methods: Post-hoc analysis conducted on a prospective MASLD cohort. All participants underwent baseline liver stiffness measurement (LSM) using SuperSonic Imagine (SSI) two-dimensional shear wave elastography (2D-SWE) and were surveilled every 6-12 months. Exclusion criteria were less than 6 months follow-up, unavailable LSM-SSI, prior HCC. Primary outcome was HCC, with hepatic decompensation and portal vein thrombosis (PVT) as competing risks. To improve risk stratification, LSM-SSI optimized cut-offs were applied: <7.4 kPa to rule-out advanced fibrosis, ≥15.6 kPa to rule-in cirrhosis, based on recent meta-analytic data, and were integrated in different risk stratification algorithms. Results: Among 352 patients with a median follow-up of 31 (14.1-57.8) months, 257 (73%) had LSM-SSI <7.4 kPa, 67 (19%) between 7.4-15.6 kPa, and 28 (8%) ≥15.6 kPa. During follow-up, 9 (2.6%) developed HCC, 6 (1.7%) decompensation, 2 (0.6%) PVT. No events occurred in patients with LSM-SSI <7.4 kPa. In the 7.4-15.6 kPa group, HCC and decompensation occurred in 3 (4.5%) and 1 (1.5%), respectively. For non-cirrhotic patients (LSM-SSI <15.6 kPa), LSM-SSI was significantly associated with HCC risk (HR 1.542, p<0.0001). Following multivariate analysis, independent HCC predictors were: LSM-SSI (HR 1.052, 95% CI 1.030-1.075, p<0.001), type 2 diabetes mellitus (HR 4.555, 95% Ci 1.091-19.012, p=0.038), and gamma-glutamyl transferase (HR 1.004, 95% CI 1.001-1.006, p=0.003). A two-step non-invasive algorithm combining LSM-SSI and the PLEASE score yielded 100% negative predictive value and 89.5% accuracy in identifying patients for HCC surveillance. Conclusion: HCC is the leading liver-related complication in non-cirrhotic MASLD. LSM-SSI <7.4 kPa effectively excludes high-risk patients. A two-step algorithm further enhances risk stratification and surveillance precision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.